These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38895887)

  • 1. Real-world implementation of the David-Carroll buprenorphine protocol for pain management in sickle cell disease.
    Torres C; Galadanci N; Osborn J; Kanter J
    Am J Hematol; 2024 Sep; 99(9):1834-1836. PubMed ID: 38895887
    [No Abstract]   [Full Text] [Related]  

  • 2. Buprenorphine for Chronic Pain in a Pediatric Patient With Sickle-Cell Disease.
    Irwin M; Gunther W; Keefer P; Saul D; Singh SA; Wright J; Smith MA
    J Pain Symptom Manage; 2021 Nov; 62(5):1086-1091. PubMed ID: 33864846
    [No Abstract]   [Full Text] [Related]  

  • 3. "Buprenorphine, It Works so Differently": Adults with Sickle Cell Disease Describe Transitioning to Buprenorphine for Treatment of Chronic Pain.
    Prince E; Loeser P; Early M; Carroll CP; Lanzkron S; Pecker LH
    J Pain; 2024 Mar; 25(3):632-641. PubMed ID: 37742907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Opioid Drug Epidemic and Sickle Cell Disease: Guilt by Association.
    Ruta NS; Ballas SK
    Pain Med; 2016 Oct; 17(10):1793-1798. PubMed ID: 27152018
    [No Abstract]   [Full Text] [Related]  

  • 5. Ambulatory microdose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease.
    Buchheit BM; Joslin T; Turner HN; Wong TE
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28766. PubMed ID: 33111401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sickle cell anemia and pain: will data prevail over beliefs?
    Payne R
    Ann Emerg Med; 2009 May; 53(5):596-7. PubMed ID: 19380037
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral morphine protocol for sickle cell crisis pain.
    Conti C; Tso E; Browne B
    Md Med J; 1996 Jan; 45(1):33-5. PubMed ID: 8569458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic opioid use in patients with sickle cell disease.
    Mo G; Jang T; Stewart C; Khoury L; Ferguson N; Egini O; Muthu J; Dutta D; Salifu M; Lim SH
    Hematology; 2021 Dec; 26(1):415-416. PubMed ID: 34102090
    [No Abstract]   [Full Text] [Related]  

  • 9. Opioid treatment for acute and chronic pain in patients with sickle cell disease.
    Carroll CP
    Neurosci Lett; 2020 Jan; 714():134534. PubMed ID: 31593753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease.
    Han J; Saraf SL; Gowhari M; Jain S; Molokie RE; Gordeuk VR
    Am J Hematol; 2019 Jan; 94(1):E5-E7. PubMed ID: 30299555
    [No Abstract]   [Full Text] [Related]  

  • 11. Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature.
    Uprety D; Baber A; Foy M
    Ann Hematol; 2014 May; 93(5):769-71. PubMed ID: 24232306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine in cancer pain.
    Davis MP
    Support Care Cancer; 2005 Nov; 13(11):878-87. PubMed ID: 16010532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Intravenous Opioid Shortage on Managing Pain Crisis in Sickle Cell Disease.
    Han J; Saraf SL; Gowhari M; Hussain FA; Jain S; Kavoliunaite L; Molokie RE; Gordeuk VR
    Ann Pharmacother; 2022 Feb; 56(2):222-223. PubMed ID: 34151594
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of nonopioid agents for inpatient pain management of sickle cell disease.
    Austin Szwak J
    Am J Health Syst Pharm; 2020 Jun; 77(13):1007-1008. PubMed ID: 32470105
    [No Abstract]   [Full Text] [Related]  

  • 15. To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine.
    Anderson TA; Quaye ANA; Ward EN; Wilens TE; Hilliard PE; Brummett CM
    Anesthesiology; 2017 Jun; 126(6):1180-1186. PubMed ID: 28511196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a dedicated day hospital for management of acute sickle cell pain.
    Adewoye AH; Nolan V; McMahon L; Ma Q; Steinberg MH
    Haematologica; 2007 Jun; 92(6):854-5. PubMed ID: 17550862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transdermal System-Buprenorphine and Fentanyl].
    Sakurai H
    Masui; 2015 Nov; 64(11):1145-50. PubMed ID: 26689065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Chronic Pain and Opioid Usage in Adult Sickle Cell Disease Patients Referred to a Comprehensive Pain Clinic.
    Zoheiry N; Alkokani M; Ward R; Mailis A
    Pain Med; 2016 Nov; 17(11):2145-2146. PubMed ID: 27880652
    [No Abstract]   [Full Text] [Related]  

  • 19. IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies.
    Dampier CD; Smith WR; Wager CG; Kim HY; Bell MC; Miller ST; Weiner DL; Minniti CP; Krishnamurti L; Ataga KI; Eckman JR; Hsu LL; McClish D; McKinlay SM; Molokie R; Osunkwo I; Smith-Whitley K; Telen MJ;
    Clin Trials; 2013 Apr; 10(2):319-31. PubMed ID: 23539110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes.
    Dampier CD; Wager CG; Harrison R; Hsu LL; Minniti CP; Smith WR;
    Am J Hematol; 2012 Oct; 87(10):E71-4. PubMed ID: 22886853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.